But it dropped after hours

It's true that IXHL experienced a drop of 12.3% in its stock price after hours on July 24, 2025. This post-market decline could be influenced by a variety of factors, including: 1. **Regulatory Hurdles**: The company's recent filing for a common stock offering of up to $100 million might have caused some uncertainty among investors. 2. **Financial Performance**: Despite the positive developments, the company's financials show a net loss of $3.97 million and a diluted EPS of -$0.2 for the latest quarter. The growth rates for net income and diluted EPS are 34.21% and 47.37%, respectively, indicating improvement but still negative numbers. 3. **Market Sentiment**: The stock's extreme volatility, with a recent 149.94% monthly increase and a 361.19% yearly decrease, suggests that while there is potential for high returns, there are also considerable risks. |code|Ticker|Name|Date|Total Revenue YoY|Total Revenue|market_code| |---|---|---|---|---|---|---| |IXHL|IXHL.O|Incannex Healthcare|2024 Q4||12000|186| |IXHL|IXHL.O|Incannex Healthcare|2025 Q1||74000|186| |IXHL|IXHL.O|Incannex Healthcare|2025 Q2||12000|186| |code|Ticker|Name|Date|Net Income YoY|Net Income|market_code| |---|---|---|---|---|---|---| |IXHL|IXHL.O|Incannex Healthcare|2024 Q4|-54.791566842357454|-6461000|186| |IXHL|IXHL.O|Incannex Healthcare|2025 Q1|-646.5564738292011|-5420000|186| |IXHL|IXHL.O|Incannex Healthcare|2025 Q2|-12.459454302614006|-5894000|186| |IXHL|IXHL.O|Incannex Healthcare|2025 Q3|34.206599237274084|-3968000|186| |code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code| |---|---|---|---|---|---|---| |IXHL|IXHL.O|Incannex Healthcare|2025 Q1|-262.49999999999994|-0.29|186| |IXHL|IXHL.O|Incannex Healthcare|2025 Q2|0|-0.33|186| |IXHL|IXHL.O|Incannex Healthcare|2025 Q3|47.368421052631575|-0.2|186| Investors should consider these factors and monitor any updates from the company to gauge its future prospects. It's also important to keep a long-term perspective and consider the potential for growth in the biotech sector, despite the inherent risks.